Skip to main content
. 2019 Mar 18;2019:9864841. doi: 10.1155/2019/9864841

Table 1.

Effect of combination of FZ and BS on IL-1β, TNF-α, and IFN-γ(X-±S).

Group IL-1β/pg·mL−1 TNF-α/pg·mL−1 IFN-γ/pg·mL−1
A group 217.39±61.22 135.20±17.86 154.23±43.04
B group 731.26±156.34### 164.24±18.82# 506.03±191.55##
C1 group 547.62±172.16 145.05±17.85 198.84±54.15∗∗
C2 group 262.96±191.44∗∗∗ 143.20±18.85 182.98±88.86∗∗
D1 group 535.62±154.12 146.37±24.72 209.58±69.74
D2 group 375.62±143.54∗∗∗ 148.54±26.84 186.47±71.19∗∗
Dexamethasone group 239.42±102.37∗∗∗ 140.30±19.10 185.88±67.94∗∗

Significant differences were based on independent sample t-test.

# P < 0.05, compared with control group; ##P < 0.01, compared with control group; ###P < 0.001, compared with control group.

P < 0.05, compared with model group; ∗∗P < 0.01, compared with model group; ∗∗∗P < 0.001, compared with model group

Healthy control group (A). AIA model group (B). Therapy group (C1). Efficacy enhancing combination group (C2). Toxicity group (D1). Toxicity reducing combination group (D2). Dexamethasone group (DG).